KNIGHT CAPITOL CONSULTANTS for GENZYME CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board. General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics.
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Prof Staff, House Appropriations Committee |
Medicare/Medicaid MMM
Budget and deficit reduction proposals that may affect the Medicare and Medicaid programs, including issues related to End Stage Renal Disease and Average Sales Price calculations - The Sequestration Transparency Act (H.R. 5872); the FY 2013 Budget Resolution (H. Con. Res. 112); and the American Taxpayer Relief Act (P.L. 112-240).
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (previously listed) |
Pharmacy PHA
S. 606, Creating Hope Act of 2011, S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act, The Food and Drug Administration Safety and Innovation Act (PL 112-144) and amendments considered, including the Faster Access to Specialized Treatments Act (H.R. 4132) and the Transforming the Regulatory Environment to Accelerate Access to Treatment (TREAT) Act (S. 2113). Assess potential impact of sequestration on public health/food and drug programs (HR 8/PL 112-240).
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (previously listed) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.